Editas Medicine Inc
NASDAQ:EDIT
Intrinsic Value
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. [ Read More ]
The intrinsic value of one EDIT stock under the Base Case scenario is 11.51 USD. Compared to the current market price of 5.68 USD, Editas Medicine Inc is Undervalued by 51%.
Valuation Backtest
Editas Medicine Inc
Run backtest to discover the historical profit from buying and selling EDIT stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Editas Medicine Inc
Current Assets | 340.8m |
Cash & Short-Term Investments | 323.1m |
Receivables | 10.2m |
Other Current Assets | 7.5m |
Non-Current Assets | 158.3m |
Long-Term Investments | 104m |
PP&E | 45.7m |
Other Non-Current Assets | 8.6m |
Current Liabilities | 63.2m |
Accounts Payable | 8.3m |
Accrued Liabilities | 46.7m |
Other Current Liabilities | 8.2m |
Non-Current Liabilities | 86.8m |
Other Non-Current Liabilities | 86.8m |
Earnings Waterfall
Editas Medicine Inc
Revenue
|
78.1m
USD
|
Operating Expenses
|
-247.3m
USD
|
Operating Income
|
-169.2m
USD
|
Other Expenses
|
16m
USD
|
Net Income
|
-153.2m
USD
|
Free Cash Flow Analysis
Editas Medicine Inc
What is Free Cash Flow?
EDIT Profitability Score
Profitability Due Diligence
Editas Medicine Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Editas Medicine Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
EDIT Solvency Score
Solvency Due Diligence
Editas Medicine Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Editas Medicine Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
EDIT Price Targets Summary
Editas Medicine Inc
According to Wall Street analysts, the average 1-year price target for EDIT is 16.17 USD with a low forecast of 7.07 USD and a high forecast of 28.35 USD.
Ownership
EDIT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
EDIT Price
Editas Medicine Inc
Average Annual Return | 4.9% |
Standard Deviation of Annual Returns | 98.4% |
Max Drawdown | -94% |
Market Capitalization | 464.4m USD |
Shares Outstanding | 81 813 800 |
Percentage of Shares Shorted | 28.1% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.
Contact
IPO
Employees
Officers
The intrinsic value of one EDIT stock under the Base Case scenario is 11.51 USD.
Compared to the current market price of 5.68 USD, Editas Medicine Inc is Undervalued by 51%.